EMERYVILLE, Calif. and BRISBANE, Australia--(BUSINESS WIRE)--Peplin, Inc. (ASX: PLI) today announced financial results for the quarter ended 31 December 2008, reporting a US$33.8 million cash balance. Peplin believes this cash balance will be sufficient to fund Phase III testing of Peplin’s lead product, PEP005 (ingenol mebutate) Gel, for actinic (solar) keratosis (AK). This topical gel is applied by the patient for the treatment of AK, a common pre-cancerous skin condition, which affects areas on both the head and body.
